Health Economics›Clear cell renal cell carcinoma›Metastatic disease first-line

Metastatic disease first-line

Clear cell renal cell carcinoma · 23 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 15 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	—	~52	~R 14 921 674 PFS proxy · indirect	1
Cabozantinib, Ipilimumab, Nivolumab Variant #01 Partial	—	R 184 762	28d	—	—	27	R 2 134 118 PFS proxy	1
Cabozantinib monotherapy Variant #01	—	R 151 638	28d	8.6 mo	—	2	R 303 276 PFS proxy	2
Regorafenib monotherapy Variant #01	—	R 132 655	28d	~3.6 mo	~9.4 mo	~2	~R 265 310 PFS proxy · indirect	15
Lenvatinib and Pembrolizumab Variant #01	—	R 128 546	21d	23.9 mo	—	2	R 257 092 PFS proxy	3
Axitinib and Pembrolizumab Variant #01	—	R 98 039	21d	15.7 mo	46.6 mo	2	R 196 077 PFS proxy	6
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	—	52.7 mo	9	R 707 538 PFS proxy	3
Everolimus and Lenvatinib Variant #01	—	R 48 788	21d	14.7 mo	—	2	R 97 575 PFS proxy	1
Cabozantinib and Nivolumab Variant #01 Partial	—	R 30 328	14d	16.6 mo	43.6 mo	53	R 1 607 364 PFS proxy	5
Erlotinib and Bevacizumab Variant #01	—	R 26 036	28d	9.9 mo	—	52	R 1 353 852 PFS proxy	1
Pazopanib monotherapy Variant #01	—	R 22 754	28d	9.2 mo	22.9 mo	26	R 591 593 PFS proxy	3
Axitinib monotherapy Variant #01	—	R 21 402	28d	10.1 mo	21.7 mo	2	R 42 804 PFS proxy	2
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	8.5 mo	—	52	R 992 271 PFS proxy	1
Bevacizumab and Interferon alfa-2a Variant #01 Partial	—	R 19 082	14d	9.8 mo	20.8 mo	2	R 38 164 PFS proxy	4
Axitinib and Toripalimab Variant #01 Partial	—	R 16 051	21d	18.0 mo	—	36	R 577 849 PFS proxy	2
Sorafenib monotherapy Variant #04	—	R 16 002	28d	6.8 mo	23.3 mo	2	R 32 005 PFS proxy	4
Sunitinib monotherapy Variant #01	—	R 15 867	42d	9.1 mo	34.0 mo	2	R 31 733 PFS proxy	24
Gemcitabine and Sunitinib Variant #01	—	R 11 277	21d	—	—	~2	~R 22 555 indirect	—
Axitinib and Avelumab Variant #01 Partial	—	R 10 701	14d	13.6 mo	43.2 mo	2	R 21 402 PFS proxy	3
High-dose Interleukin-2 Variant #01 Partial	—	—	84d	—	—	~4	—	—
Tivozanib monotherapy Variant #01 Partial	—	—	28d	11.9 mo	—	2	—	1
Placebo Partial	—	—	—	—	~15.2 mo	—	—	1
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	5.4 mo	21.3 mo	11	—	6

23 of 23 regimens shown